Replies to post #5285 on Dendreon Corp fka DNDNQ

[walldiver]

<<The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004). Median survival time was 19.2 months (95% CI, 17.5 to 21.3 months) in the D3P arm, 17.8 months (95% CI, 16.2 to 19.2 months) in the D1P arm, and 16.3 months (95% CI, 14.3 to 17.9 months) in the MP arm. More patients survived 3 years in the D3P and D1P arms (18.6% and 16.6%, respectively) compared with the MP arm (13.5%).>>

Interesting. Yes, the power of large numbers. Basically, for the approved regimen it was a 2.9-month median survival benefit, with 18.6% vs 13.5% in three-year survival. Granted, the trial population was split 50-50 between symptomatic and asymptomatic, and the numbers were a lot better for the asymptomatic subgroup comparison.